An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
ApexOnco Front Page
Recent articles
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
ESMO and the Triple Meeting approach.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
BNT329 enters the clinic, as do four other new ADCs.
